Comparative Pharmacology
Head-to-head clinical analysis: DEXACORT versus FERNISOLONE P.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXACORT versus FERNISOLONE P.
DEXACORT vs FERNISOLONE-P
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist that modulates gene expression to produce anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
FERNISOLONE-P is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators like prostaglandins and leukotrienes.
Oral: 0.75-9 mg/day in divided doses; IV: 0.5-9 mg/day every 6-12 hours; IM: 4-20 mg every 2 weeks.
5-60 mg orally once daily or in divided doses; intravenous, intramuscular, or intra-articular administration per specific indication.
None Documented
None Documented
Plasma terminal elimination half-life is 2.8-3.5 hours in adults, but the biological half-life (duration of HPA axis suppression) is 24-36 hours due to prolonged receptor occupancy
3.5 hours; in renal impairment (CrCl <30 mL/min) may extend to 8-10 hours, requiring dose adjustment
Renal (approximately 80% as inactive metabolites, <5% unchanged), biliary/fecal (minor, approximately 15-20%)
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Corticosteroid
Corticosteroid